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Sarcoidosis is an inﬂammatory disorder of unknown etiol-
ogy, diagnosed by the presence of noncaseating granulomas
on histopathological examination. The disease involves the
respiratory system in more than 90% of cases. The most
frequent extrapulmonarymanifestations are the eyes, lymph
nodes, joints, and the skin, although essentially any organ
system can be involved.1
Whoandwhen to treat, aswell as durationof treatment are
the most compelling clinical conundrums. Systemic corticos-
teroids are generally acknowledged as ﬁrst-line treatment of
systemic sarcoidosis, although the scientiﬁc evidence for this
approach is scarce.2 Although potentially treatable in a vast
majority of patients, sarcoidosis activity may linger in some
cases under corticosteroids necessitating a longer and persist-
ing courseof treatmentusingacombinationof steroids andso-
called steroid-sparing drugs or “disease modiﬁers” in some
cases.3 Partial or complete treatment refractoriness and drug
toxicity are the most important limiting factors in the success
of pharmacological treatment of sarcoidosis. Although remis-
sion occurs in about two-thirds of patients after prolonged
treatment (1–2 years), the remaining patients will evolve
toward chronic or even progressive disease.4 Therefore, end-
stage organ failure as a direct result of sarcoidosis and/or as a
result of treatment toxicity is a valid indication for solid organ
transplantation (SOT) in selected patients.
Lung Transplantation in Pulmonary
Sarcoidosis
With a proportion of 2.5% of all worldwide referrals for lung
transplantation (LTx) between 1995 and 2011, sarcoidosis
can be considered a marginal stakeholder in this respect.5
Nevertheless, some reports suggest an increase of referrals
for LTx during recent years. The selection criteria for referral
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Abstract Sarcoidosis is a chronic systemic inﬂammatory disease which is histopathologically
characterized by the presence of noncaseating granulomas. When the extent of the
disease is limited, without endangering the function of affected organs, clinical
observation can be sufﬁcient given that in a majority of cases, inﬂammation will
subside with time. In more advanced sarcoidosis, especially when one or more speciﬁc
organs are threatened, immunomodulatory treatment, of which steroids are the key
element, over a prolonged period of time, in general, may attenuate disease activity.
Treatment-refractory sarcoidosis (due to the lack of efﬁcacy, drug toxicity or intoler-
ability) may be progressive and, although infrequent, can result in end-stage organ
failure. In these selected cases, solid organ transplantation (SOT) should be considered.
In this article, SOT is positioned within the organ-speciﬁc treatment of systemic
sarcoidosis and data on outcome after transplantation are discussed.
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and listing of sarcoidosis patients for LTx are comparable to
what has been put forward for other end-stage ﬁbrotic lung
disease (e.g., idiopathic pulmonary ﬁbrosis [IPF]).6 The Inter-
national Society for Heart and Lung Transplantation recently
updated the disease-speciﬁc referral criteria for LTx, stating
that for ﬁbrotic lung disease (including sarcoidosis), New
York Heart Association functional Class III or IV, or any of the
following factors are critical: hypoxemia at rest, hypoxemia
during exercise, pulmonary hypertension (systolic pulmon-
ary arterial pressure [PAP] > 35 mm Hg on echocardiogra-
phy, or mean PAP > 25 mm Hg on right heart
catheterization, or elevated right atrial pressure > 15 mm
Hg), forced vital capacity < 80% predicted, or diffusion ca-
pacity < 40% predicted.5–7 Progressive pulmonary ﬁbrosis,
recurrent respiratory infection, and pulmonary hyperten-
sion are the leading contributors to respiratory failure and as
a result important causes of mortality in pulmonary sarcoi-
dosis. Severe and progressive pulmonary sarcoidosis, which
in clinical practice equals progressive ﬁbrotic disease war-
rants prompt referral for possible LTx.7Moreover,waiting list
mortality in patients with ﬁbrotic, restrictive lung disease is
the highest among all indications for transplantation, and
may increase up to 25 to 30% with increasing time spent on
the waiting list.8 Therefore, timely referral for transplant
evaluation is crucial in these patients.5–7 In clinical practice,
however, timely referral for transplantation is not always so
obvious. On the contrary, quantitative models predicting
mortality in sarcoidosis are lacking and lung functional
parameters do not always reﬂect clinical behavior of the
disease.9 Therefore, rules of thumb to guide clinical decision
making and assessing disease severity are nonexistent. Re-
ferral for LTx should therefore be assessed on a case-by-case
basis, considering the patient as a whole and looking for
criteria of end-stage or refractory disease. Single-sided or
unilateral LTx might still be a valid choice for selected
sarcoidosis patients, in whom the burden of immunosup-
pression-triggered respiratory tumors in the remaining na-
tive lung plays a less important role compared with IPF. The
choice for single LTx is taken based on local institutional
factors such as donor organ availability and waiting list
mortality.8 Nevertheless, infectious complications of ﬁbrotic
pulmonary sarcoidosis, such as recurrent suppurative infec-
tions, bronchiectasis, or chronic mold infections, as well as
better long-term survival in bilateral versus single LTx have
nowadays prompted many centers to perform bilateral LTx
instead of single LTx in ﬁbrotic pulmonary disease.7,8
Early outcome after LTx might be disadvantageous for
sarcoidosis patients. A 2014 meta-analysis of 13 studies
involving a total number of 10,042 LTx recipients and com-
prising 98 cases of sarcoidosis stated that sarcoidosis as
indication for LTx leads to a 50% prevalence of primary graft
dysfunction (PGD) and was shown to be an independent risk
factor for PGD (odds ratio: 4.25, 95% conﬁdence interval:
1.09–16.52) using chronic obstructive pulmonary disease as
benchmark and irrespective of lung transplant type (single
or bilateral).10 End-stage ﬁbrotic disease such as sarcoidosis
is associated with more difﬁcult surgical pleural dissections
and thus a higher risk of postoperative hemothorax.11,12
Indeed, an increased incidence of hemothorax up to 25%
has been reported in sarcoidosis, resulting in decreased
ventilator-free days, increased length of stay on intensive
care unit, and increased hospital length of stay after LTx.12
Even though sarcoidosis is an independent predictor of early
mortality as a result of an increase in PGD among these
patients,12 many reports conclude that long-term outcomes
after LTx for sarcoidosis are similar to other lung dis-
eases.13–15 Therefore, end-stage pulmonary disease due to
sarcoidosis indeed is a justiﬁed indication for LTx, given the
achievable survival beneﬁt for appropriately selected pa-
tients with high risk of short-term mortality.16 The largest
cohort in the literature reports on 695 cases of LTx for
sarcoidosis out of a total of 20,896 LTx recipients (3.3%)
over a 25-year time period.17 These authors show that
sarcoid LTx recipients have similar median survival rates
compared with the nonsarcoid LTx recipients. Regression
analysis did not identify sarcoidosis as an independent factor
for survival after LTx. Moreover, sarcoid LTx recipients did
not have higher incidences of bronchiolitis obliterans syn-
drome (BOS), recurrent hypoxemia after LTx, and seemed to
have lower rates of redo LTx, despite the fact that sarcoid can
recur after LTx. Another report endorses the observation that
BOS is not more common in sarcoid LTx recipients than in
others.18
Posttransplant recurrence of noncaseating granulomas in
lung allografts despite continuing immune suppression has
been reported in up to 35% of cases; however, these ﬁndings
usually are not clinically relevant (illustrated in ►Fig. 1).19
These recurrent granulomas are originating from the recipient,
asprovenby thepresenceofdonor/recipientchimerismonlung
biopsies.20 A Danish article describes a post-LTx sarcoid gran-
uloma recurrence rate of 30%, interestingly, all cases of disease
recurrence were documented by histopathological detection
during surveillance bronchoscopies, without any clinical or
radiological signs of sarcoid disease. Recurrent granulomas
had no lung functional consequences and did not affect overall
survival.21 These ﬁndings were corroborated by a study of the
ClevelandClinic, reportingon30LTxprocedures for sarcoidosis.
Histopathological recurrence of noncaseating granulomas was
noted in seven patients (23%) and was histologically detected
on surveillance bronchoscopy in all patients. Only one out of
these sevenpatientshad radiological abnormalities compatible
withpulmonary sarcoidosis, and sarcoidosis recurrencedidnot
impact on post-LTx survival rates.22 The observation that most
recurrentcasesaresubclinicalwasconﬁrmedbyanother report
stating that in only one out of three cases of recurrent pul-
monary sarcoidosis, radiological changes are apparent (a pos-
teriori assessment).19 One article reports on a case of sarcoid
recurrence after single LTx, necessitating redo LTx with even-
tually again sarcoid recurrence in the second lung allograft in
the same patient.23 This again highlights the beneﬁt of per-
forming bilateral LTx (which implies more lung functional
“reserve” in case of disease recurrence) instead of single LTx.
Nevertheless, long-term outcomemay still be compromised in
some of these patients in case of progressive disease after post-
LTx sarcoid recurrence, as is illustrated in a case from the
current authors’ center (►Fig. 2).
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Extrapulmonary Sarcoidosis
A multicenter case–control study on clinical characteristics
of sarcoidosis in the United States (A Case Control Etiologic
Study of Sarcoidosis) showed that half of all 736 sarcoidosis
patients included in the study had both pulmonary and
coexisting extrapulmonary sarcoidoses.24 Only 2% of all
study subjects were characterized with isolated extrapul-
monary disease. Although some have questioned whether
the studied cohort was representative for the general patient
population, these proportions are far above what is esti-
mated based on clinical expertise, showing that the search
for extrapulmonary sarcoidosis needs to be addressed more
thoroughly. Extrapulmonary disease manifestations may
lead to signiﬁcant morbidity and should therefore be ad-
dressed early in the course of the disease, although subcli-
nical ﬁndings in nonvital organ systems may not lead to
therapeutic consequences. Renal, cardiac, and hepatic sar-
coidoses are discussed separately with an emphasis on the
positioning and the outcome of transplantation for these
indications. Estimated frequencies of extrapulmonary organ
involvement are summarized in ►Fig. 3.
Renal Disease and Kidney Transplantation in
Sarcoidosis
Renal involvement in sarcoidosis can be the result of differ-
ent pathophysiological mechanisms, which can act both
independently or in combination. Granulomatous lesions
may produce calcitriol leading to an increased urinary ex-
cretion of calcium. Hypercalciuria occurs in about half of
sarcoidosis patients and generally precedes development of
hypercalcemia, which occurs in 10% of cases of sarcoidosis,
whenever serum calcium is abundantly higher than the
excretion potential of the kidney. Hypercalciuria and hyper-
calcemia as such may progress to renal insufﬁciency.25
Tubulointerstitial nephritis can occur as a direct conse-
quence of systemic sarcoidosis. Histological ﬁndings are
often not speciﬁc for sarcoidosis because these cases of
nephritis may be characterized by the absence of granulo-
mas. Therefore, infection and drug hypersensitivity should
be clinically excluded, as these are more frequent causes of
interstitial nephritis. The exact prevalence of interstitial
nephritis in the context of sarcoidosis is not well known. A
single-center, retrospective study on more than 10,000
kidney biopsies revealed a deﬁnite histopathological diag-
nosis (noncaseating granulomatous interstitial nephritis) in
0.18%. In a subgroup of patients diagnosed with sarcoidosis
prior to kidney biopsy, this number increased to 37%.26 A
third pathway to renal injury in sarcoidosis is nephrocalci-
nosis and/or nephrolithiasis, occurring as a result of hyper-
calcemia. An article on histopathology of kidney biopsy in
sarcoidosis patients reports on 19 patients with noncaseat-
ing granulomatous interstitial nephritis, of whom 7 pre-
sented with hypercalcemia, but only 3 had evidence of
microcalciﬁcations.26 Moreover, other renal disease such
Fig. 1 Recurrence of sarcoidosis with stable pulmonary function after bilateral lung transplantation in a 41-year-old man. Evolution of radiology
(consecutive chest CTs pretransplant, at 3, 6 months, and 1–6 years posttransplant) and of pulmonary function (forced vital capacity, L, top and forced
expiratory volume in 1 second, L, bottom) over time after bilateral LTx for sarcoidosis in a 41-year-oldman. Recurrence of sarcoidosis, despite maintenance
treatment with methylprednisolone, cyclosporine (later tacrolimus), and azathioprine was diagnosed on POD 360 by means of CT, demonstrating
micronodules inupper lobesand transbronchial biopsies, demonstrating thepresenceofnoncaseatinggranulomas.Over timeafter transplantationbilateral
pleural thickening, diffuse centrilobular, and ﬁssural micronodules (i.e., typical perilymphatic distribution) were evident, despite which pulmonary function
remained stable. CT, computed tomography; Ltx, lung transplantation; POD, postoperative day.
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as immunoglobulin A nephropathy coexisting with one of
the renal conditions mentioned earlier is not uncommon.27
Hydronephrosis as a result of retroperitoneal inﬁltration or
inﬂammation and as a result of mechanical compression
(e.g., lymphadenopathy) are theoretically also possible, but
infrequently reported.26–28 Patients with sarcoidosis may
well be affected by renal insufﬁciency, but diabetic or
vascular nephropathy is more likely in these cases than
sarcoid-induced renal insufﬁciency. Sarcoidosis-related
end-stage renal disease is an exception in clinical practice,
although a signiﬁcant degree of renal insufﬁciency with
evidence of hypercalcemia as a contributing factor has
been reported in a retrospective series.28 Both sarcoid-
related interstitial nephritis and hypercalcemia respond
well to treatment with systemic steroids in combination
with auxiliary measures for calcium control (avoidance of
exogenous calcium/vitamin D, diuretics, bisphosphonates).
Adjunctive treatment with ketoconazole, hydroxychloro-
quine, azathioprine, or mycophenolate mofetil have rarely
been reported in cases of granulomatous interstitial
nephritis unresponsive to systemic steroids.29 In conclusion,
end-stage renal disease as a direct result of sarcoid nephritis
is rare but can be an indication for kidney transplantation
(KTx) in very selected cases in which pharmacological treat-
ment fails.
Outcome of KTx in the context of sarcoidosis-related renal
insufﬁciency is comparable to overall outcomes after KTx for
other indications. Nevertheless, reactivation of known sar-
coidosis has been described in the setting of KTx.30 In the
previously mentioned retrospective report on kidney histo-
pathology,26 a total of 2,331 kidney biopsies from renal grafts
were assessed, among which two were obtained from grafts
of patients who underwent KTx because of biopsy-proven
renal sarcoidosis. One of these patients was found to have
recurrence of granulomas on posttransplant kidney biopsy
(without infections or nephrotoxic drugs), although without
any signs of renal graft failure. Themost detailed examples of
recurrence after KTx were reviewed in a case series of 18
patients who underwent KTx with a previous diagnosis of
sarcoidosis. In ﬁve patients (27%) who had disease recur-
rence, two developed renal sarcoidosis and three had extra-
renal manifestations, a mean period of 13 months following
Fig. 2 Recurrence of sarcoidosis with decline of pulmonary function after bilateral lung transplantation in a 40-year-old man. Evolution of
radiology (consecutive chest CTs, left panel) and of pulmonary function (right panel, forced vital capacity, %predicted, top and forced expiratory
volume in 1 second, %predicted, bottom) over time after bilateral LTx for sarcoidosis in a 40-year-old man. Recurrence of sarcoidosis was
diagnosed on POD 393 by means of transbronchial biopsies demonstrating the presence of noncaseating granulomas. Thereafter, despite
maintenance treatment with prednisone, tacrolimus, and mycophenolate, pulmonary function progressively worsened over the subsequent
5 years due to progressive pulmonary ﬁbrosis, resulting in restrictive CLAD with respiratory insufﬁciency. Chest CT on POD 2,993, shortly before
redo transplantation, demonstrates marked bilateral pleural and ﬁssural thickening, as well as subpleural consolidation. Shortly after redo
transplantation, the patient unfortunately succumbed due to postoperative sepsis. Explant lungs (demonstrated in the insets of the right
explanted lung, showing ex vivo CT and gross histology) demonstrated signiﬁcant ﬁbrosis with lymphatic spread, involving intralobular septae
and visceral pleura. (Sub)pleural ﬁbrosis (white arrow) is demonstrated in detail on micro-CTof a core biopsy of this explant lung. The presence of
noncaseating granulomas (black arrows) is illustrated on histology of transbronchial and endobronchial biopsies at POD 393 (hematoxylin and
eosin stain, 100 left and 200 right). CLAD, chronic lung allograft dysfunction; CT, computed tomography; Ltx, lung transplantation; POD,
postoperative day.
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KTx. All patients were receiving immunosuppression (in-
cluding low-dose prednisolone) at the time. Guided by these
observation, sarcoidosis relapse may occur in up to a quarter
of patients after KTx and may negatively impact on renal
graft survival.31
Cardiac Disease and Heart Transplantation
in Sarcoidosis
Exact prevalence of cardiac sarcoidosis is hard to balance
between clinical reporting and data from autopsy studies. In
general, cardiac involvement is clinically estimated at 5% in
sarcoidosis patients,32 although autopsy studies reveal a
much higher prevalence of 25% and above.33 Therefore, it
is quite conceivable to assume a high rate of subclinical
involvement, making overt cardiac sarcoidosis a rather rare
manifestation. Even in the presence of cardiac failure, a
correct diagnosis of cardiac sarcoidosis is often hard to
achieve. This is demonstrated by a report on histopathologic
examination of 314 explanted hearts, revealing only 8 cases
(2.5%) of cardiac sarcoidosis, none of which was diagnosed
prior to transplantation.34 On the contrary, cardiac sarcoi-
dosis is a potential lethal disorder with low survival rates if
left untreated. Endocardial, myocardial, and pericardial ab-
normalities may be present on histology. Cardiac sarcoidosis
may present as atrioventricular or intraventricular heart
block, ventricular tachycardia, (un)sustained ventricular
ﬁbrillation, cardiomyopathy, or in the most dramatic cases
sudden death.33,35 Progressive heart failure due to granulo-
matous inﬁltration of the myocardium is the main cause of
death in cardiac sarcoidosis. Overall mortality in sarcoidosis
is attributable to cardiac involvement in 13 to 85%, depend-
ing on ethnicity.35 In addition to speciﬁc cardiologic thera-
pies (antiarrhythmic drugs, angiotensin-converting enzyme
inhibitors, β-blockers, implantation of pacemaker or implan-
table cardiac deﬁbrillator), treatment of cardiac sarcoidosis
consists out of systemic steroids, although evidence for
dosing, timing, and outcome of steroid treatment is again
lacking. Some reports suggest a better outcome of left
ventricular function when methotrexate is added to steroid
treatment.36
Data on overall, long-term, transplantation-free survival
in patients with cardiac sarcoidosis are very heterogeneous
due to historic, ethnic, and methodological reasons. Articles
in the late 1970s and 1980s of cardiac sarcoidosis reported
disappointingly low survival of 27% 1 year after symptom
onset37 and 40% 5-year survival, respectively.38 In a recent
multicenter Japanese study, 5-year survival was 60 to 75%39
and another multicenter study of the early 2000s reported
transplantation-free 5-year survival rates of 60 to 70%.40 In
contrast, smaller studies in the same era reported a 5-year
survival exceeding 90%.41–43 Recently, 1-, 5-, and 10-year
transplantation-free cardiac survival rates of 97, 90, and 83%
were reported, respectively.32 Prospective data on the out-
come of cardiac sarcoidosis are even more rare. Smaller
studies looked at correlation of late gadolinium enhance-
ment on cardiac imaging (magnetic resonance imaging
[MRI]) and found cardiac mortality rates of 8 to 19% in this
speciﬁc subset of patients.44,45 These ﬁndings, however,
seem less consistent to reproduce since a prior 2008 study
demonstrated no mortality whatsoever in patients with
cardiac symptoms or radiologic (positron emission tomo-
graphy/MRI) features indicative of cardiac sarcoidosis during
a 2-year follow-up.46 Nevertheless, given the possible life-
threatening consequences, physicians should always have a
high index of clinical suspicion for possible cardiac involve-
ment in patients with sarcoidosis.
Similar to other causes of end-stage cardiac disease, heart
transplantation (HTx) should be considered in sarcoid-in-
duced heart failure when all other therapies have failed.47
Most reports on sarcoidosis and HTx are largely based on
transplantation of patients with “idiopathic” cardiac failure
(i.e., without clinical diagnosis of sarcoidosis prior to trans-
plantation), in whom sarcoidosis was detected histopatho-
logically on the explanted heart.48 Therefore, clinical practice
should be interpreted in this given context. Overall, cardiac
sarcoidosis as indication for HTx remains a rarity among HTx
recipients, with proportional estimates of 1.3 to 1.8%.48,49
Only 33 to 42% of these patients had a histology-endorsed
pretransplant diagnosis of extracardiac sarcoidosis and only
21% had biopsy-proven cardiac sarcoidosis.48,49 Interest-
ingly, some authors report an increasing number of cases
of cardiac sarcoidosis in patients listed for HTx during the
past decades. Al-Kindi and Oliveira identiﬁed a total of 150
adult patients with cardiac sarcoidosis listed for HTx
Fig. 3 Estimated frequencies of organ involvement in sarcoidosis.
(Modiﬁed from OpenStax College, Anatomy and Physiology. OpenStax
CNX. Available at: http://cnx.org/contents/14fb4ad7-39a1-4eee-
ab6e-3ef2482e3e22@8.24. Permission for publication granted by
Dove Medical Press Ltd.)
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between 1994 and 2014. During this period, a ﬁvefold
increase in the proportion of sarcoid cases with heart failure
requiring HTx was seen: 0.1% (1994–1997) to 0.5% (2010–
2014). The proportion of cardiac sarcoidosis among cases of
restrictive cardiomyopathy increased in parallel from 5 to
more than 15% during the same era.50 As one would expect
due to increased awareness and better screening methods,
similar ﬁndings on increased detection rate of cardiac sar-
coidosis were reported: a more than 20-fold increase of the
annual detection rate of cardiac sarcoidosis was seen be-
tween 1988 and 2012 in a Finnish Nationwide Study.32,50
Overall survival after HTx for sarcoidosis is reported to be
comparable to other indications for HTx: 86% at 1 year, 84%
at 5 years, and 58% at 10 years.50 Comparable overall survival
rates are reported by other authors: 92% at 1 year and 83% at
5 years in a recent study in the United Kingdom.48 Kandolin
et al report on 11 cases of HTx, out of a pool of 110 patients
followed up between 1988 and 2012, inwhom 1-year, 3-year
and 5-year survival rates were 82, 73, and 64%, respec-
tively.32 Perkel et al report a 5-year posttransplant survival
of 79%, a 1-year freedom from any treated rejection of 79%, a
5-year freedom from cardiac allograft vasculopathy of 68%,
and a 5-year freedom from nonfatal major adverse cardiac
events of 90%. All these rates were comparable to what was
found in a contemporary control group of nonsarcoid heart
and LTx recipients.49 Recurrence of sarcoidosis in the allo-
graft has been reported when tapering steroids51–53 but
seems to be rare, since no cases of recurrent cardiac sarcoi-
dosis and limited progression (0–19%) of concurrent extra-
cardiac sarcoidosis were described in some larger cohorts
during a total follow-up time of more than 20 years.48 Some
state that maintaining sarcoidosis patients on low doses of
corticosteroids after HTx may prevent sarcoid recurrence in
the allograft.51 As a result, potential disease recurrence
should not be considered a reason to withhold HTx from
patients with end-stage heart failure due to cardiac
sarcoidosis.49
Hepatic Disease and Liver Transplantation in
Sarcoidosis
Clinically, overt hepatic disease as a result of sarcoidosis is
very rare, although noncaseating granulomas of the liver are
present in up to 65% of patients with systemic sarcoidosis54
and postmortem studies demonstrated that hepatic granu-
lomas are present in 80% of patients with sarcoidosis.55
Clinically, hepatic sarcoidosis should be suspected when
patients with systemic sarcoidosis present with hepatome-
galy, right-sided hypochondric pain, elevated serum liver
function tests, and/or nodular changes of the liver parench-
yma on ultrasound or computed tomography scan. When
histologic conﬁrmation is needed (e.g., to guide treatment
decisions), liver biopsy should be pursued. Systemic corti-
coids can be effective in reducing liver size, resulting in
symptomatic relief, although its effects on number of gran-
ulomas and liver function are less convincing.56 Corticoster-
oids are less useful in changing the disease course and
evidence-based data that steroid treatment may reduce
portal hypertension or hepatic ﬁbrosis are disappointing.56
Steroid-sparing agents have been used with some success.
Azathioprine is preferred over methotrexate by some,
although both are potentially hepatotoxic.2,3 Chronic, per-
sistent hepatic inﬂammation in the context of sarcoidosis
may lead to portal hypertension in 3 to 18% of patients,
potentially causing variceal bleeding.57 Compression of por-
tal venules by intrahepatic granulomas is a possiblemechan-
istic explanation for this observation. Only a small
proportion of patients with sarcoid liver disease (6–8%)
develop secondary portal hypertension following prior pro-
gression to cirrhosis.58
In end-stage sarcoid liver disease, orthotopic liver trans-
plantation (OLTx) has been successfully used as a treatment
modality. Cases of sarcoidosis-induced end-stage liver dis-
ease account for 0.012% of the total number of liver
transplantation in the United States.59 Since clinically overt
hepatic disease is infrequent and OLTx is only performed in a
fraction of patients with end-stage liver disease, data on
outcome of OLTx in sarcoidosis are even rarer comparedwith
other SOT for sarcoidosis. A recentmulticenter article reports
on 13 cases of OLT in sarcoidosis, comprising 1.3% of all OLT
cases. Long-term outcomes were described in a case–control
method, showing that 1-, 3-, and 5-year survival rates after
OLTx did not differ between sarcoidosis patients and a
matched group of patients with primary sclerosing cholan-
gitis or primary biliary cirrhosis.60 This contrastswith earlier
observational ﬁndings of the same group reporting that
outcome after OLTx could be impaired for sarcoidosis pa-
tients compared with primary sclerosing cholangitis or
primary biliary cirrhosis (5-year graft-survival rates of 60
vs. 75%). The authors speculate that hepatic sarcoidosis
reﬂects systemic sarcoidosis, which may lead to impaired
ﬁtness of the patient before or after OLTx as a result of
extrahepatic disease.61 The observation that outcome of
OLTx for sarcoidosis is comparable to what is seen for other
OLTx indications has been conﬁrmed by others showing
allograft-survival rates to be comparable with other chole-
static and parenchyma liver diseases (86% after 5 years).62
Recurrences of granulomatous inﬂammation may occur in
the hepatic allograft and seem to be controllable with
increased doses of systemic corticosteroids.63 Bilal et al
show recurrence of hepatic sarcoidosis in 4 out of 13 patients
(31%) at 11, 112, 222 days, and 6.6 years post-OLTx,
respectively.60
Conclusion
Selection of sarcoidosis patients for organ transplantation
should be performed in a holistic approach, assessing the
potential success and side effects of immunosuppressive
therapies and the presence of extrapulmonary involvement
(e.g., neurosarcoidosis) precluding transplantation. In the
detrimental case of severe combined organ involvement,
combined organ transplantation (e.g., heart–lung, heart–
liver, lung–liver, and lung–kidney transplantation) could be
considered, as is done for other (nonsarcoidosis) transplant
indications. Sarcoidosis may recur after organ
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transplantation, but the reports discussed in this article
demonstrate that sarcoid recurrence is generally treatable
with increasing systemic corticosteroids and overall does
not lead to premature graft failure, except maybe for a
minority of recurrent cases, especially after KTx. Posttrans-
plant recurrence of sarcoidosis should therefore not be
overestimated. This may be best illustrated by data in LTx
describing incidental ﬁndings of noncaseating granulomas
during posttransplant surveillance bronchoscopy. Given
that sensitivity of transbronchial biopsies for diagnosis of
parenchymal lung disease in sarcoidosis is only 30 to 70%,
one may assume that the actual incidence of disease
recurrence after LTx is probably underestimated. Never-
theless, long-term posttransplant outcomes in these cases
are overall excellent and comparable to nonsarcoid LTx
recipients. The main reason why recurrent disease after
SOT can be considered “clinically irrelevant granulomatosis”
is probably the life-long immunosuppressive treatment of
SOT recipients, allowing sufﬁcient disease control and pre-
venting further evolution to ﬁbrosis in most patients. As a
result, possible posttransplant recurrence of sarcoidosis
should be no reason to withhold transplantation from
otherwise eligible patients suffering from end-stage organ
failure due to sarcoidosis. In general, SOT for sarcoidosis has
good long-term outcomes and may result in signiﬁcant
survival beneﬁt for appropriately selected patients with
high risk of short-term mortality.
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